Skip to main content
ARS Home » Midwest Area » Peoria, Illinois » National Center for Agricultural Utilization Research » Mycotoxin Prevention and Applied Microbiology Research » Research » Publications at this Location » Publication #331520
Title: Multilocus phylogeny and antifungal susceptibility of Aspergillus section Circumdati from clinical samples and description of A. pseudosclerotiorum sp. nov.

Author
item SIQUEIRA, J. P. - University Rovira I Virgili
item SUTTON, D. - University Of Texas Health Science Center
item GENE, J - University Rovira I Virgili
item GARCIA, D. - University Rovira I Virgili
item WIEDERHOLD, N. - University Of Texas Health Science Center
item Peterson, Stephen
item GUARRO, J. - University Rovira I Virgili

Submitted to: Journal of Clinical Microbiology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 12/30/2016
Publication Date: 1/4/2017
Citation: Siqueira, J.P.Z., Sutton, D.A., Gene, J., Garcia, D., Wiederhold, N., Peterson, S.W., Guarro, J. 2017. Multilocus phylogeny and antifungal susceptibility of Aspergillus section Circumdati from clinical samples and description of A. pseudosclerotiorum sp. nov. Journal of Clinical Microbiology. 55(3):947-958.

Interpretive Summary: A new organism was found to be infecting humans. This new organism was examined by DNA sequencing of four common genes and shown to be different from other similar appearing pathogens. The susceptibility of the new species to different antimycotic drugs was tested to indicate which drugs should be used to treat people infected with the pathogen. A class of conizoles was found to be the most effective, with amphotericin B being mostly ineffective in treatment of the disease. This work will be of interest to practitioners in the clinical setting.

Technical Abstract: A multilocus phylogenetic study was carried out to assess the species distribution in a set of 34 clinical isolates of Aspergillus section Circumdati from the USA and their in vitro antifungal susceptibility were determined against eight antifungal drugs. The genetic markers used were ITS, BenA, CaM, and RPB2, and the drugs tested were amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine. The most common species identified was A. westerdijkiae (29.4%), followed by an unknown species which was described here and named A. pseudosclerotiorum (23.5%). With less frequency were recovered A. sclerotiorum (17.6%), A. ochraceus (8.8%), A. subramanianii (8.8%), and A. insulicola and A. ochraceopetaliformis with two isolates (5.9%) each. The drugs that showed the best activity were caspofungin, micafungin, and terbinafine, while amphotericin B showed the worst activity.